Compare AAPG & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAPG | ORIC |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | 2024 | 2020 |
| Metric | AAPG | ORIC |
|---|---|---|
| Price | $13.05 | $7.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 16 |
| Target Price | ★ $44.50 | $21.79 |
| AVG Volume (30 Days) | 5.4K | ★ 1.9M |
| Earning Date | 08-19-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.91 | N/A |
| Revenue Next Year | $111.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.12 | $7.23 |
| 52 Week High | $33.09 | $14.68 |
| Indicator | AAPG | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 34.59 | 33.48 |
| Support Level | N/A | $7.40 |
| Resistance Level | $16.28 | $14.23 |
| Average True Range (ATR) | 0.44 | 0.66 |
| MACD | -0.17 | -0.07 |
| Stochastic Oscillator | 0.00 | 7.98 |
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.